山下竜也先生が共同演者でASCO2020のポスター発表しました。

Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.　ASCO2020, Abstr. 4599, J Clin Oncol 38: 2020 (suppl; abstr 4599)

Ahmed Omar Kaseb, Hop Sanderson Tran Cao, Yehia I. Mohamed, Aliya Qayyum, Luis M. Vence, Jorge M. Blando, Shalini Singh, Sunyoung S. Lee, Kanwal Pratap Singh Raghav, Lina Altameemi, Asif Rashid, Jean-Nicolas Vauthey, Kristen Carter, Ching-Wei David Tzeng, Yun Shin Chun, James C. Yao, Robert A. Wolff, James Patrick Allison, Padmanee Sharma, Kaseb’s; GI Medical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX; MD Anderson Cancer Center, Houston, TX; The University of Texas, MD Anderson Cancer Center, Houston, TX; The University of Texas, Md Anderson Cancer Center, Houston, TX; MDAndersson, Houston, KY